![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/d/df/Ranimustine_%2528Haworth%2529.svg/640px-Ranimustine_%2528Haworth%2529.svg.png&w=640&q=50)
Ranimustine
Chemical compound / From Wikipedia, the free encyclopedia
Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Cymerin |
Other names | 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea |
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H18ClN3O7 |
Molar mass | 327.72 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close
It has never been filed for FDA evaluation in the United States, where it is not marketed.